In the latest episode of The Wills Retina Report, Dr. Regillo and Dr. Hsu discuss why sustained delivery with the port ...
In part 2 of a 2-part article, Arun C. Gulani, MD, walks through the 4 patient types of the Gulani classification of refractive lens exchange, from primary vision enhancement to staged vision ...
U.S. News & World Report has released its annual list of Best Hospitals, and Bascom Palmer Eye Institute achieved the top ...
The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.
The most meaningful part is not technological. It is personal. Vision-threatening diseases create uncertainty and fear. Home ...
Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium ...
Staying on therapy results in better visual outcomes. One implication is that if we have newer drugs that last as long as 180 ...
Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's ...
In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and ...
Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results